Table 3.
Summary of literature review of oligoprogressive breast cancer and radiotherapy.
| Author | N° PTS PTS Characteristics |
Dose and Volumes | PFS | Local Control | OS |
|---|---|---|---|---|---|
| Kam TY, 2019 [30] | 22 pts Different solid tumors (MBC 7 pts tot) Both oligometastatic and oligoprogressive |
Both spinal and non-spinal metastases between 35 and 50 Gy, respectively, in five fractions | 6.6 months in OP group | 1-year LC 91.2% | Not reported |
| Shahi J, 2020 [31] | 52 pts Different solid tumors (MBC 11 pts tot) Both local progressions, oligometastatic and oligoprogressive |
SBRT dose was 35 Gy (range, 30–50 Gy in 5 fr) with a median biologically effective dose of 59.5 Gy (range, 48–100 Gy) | Median PFS was 4.0 months (95% confidence interval, 2.8–7.3) | LF was 9.0% at 2 years | OS was 31.7 months (95% confidence interval, 23.8–87.5) |
| Tsai TJ, 2021 CURB Trial [32] |
102 pts Different solid tumor (44 MBC, 22 for each arm of randomization) Patients were randomized 1:1 between SBRT to all progressive sites plus palliative standard of care (SOC) vs. palliative SOC only |
NA | No difference in median PFS was seen in the breast cohort (18 weeks with SBRT vs. 17 weeks with SOC; p = 0.5). | NA | NA |
| Ramadan S, 2022 [33] | 81 pts Different solid tumor (12 MBC tot) Only olioprogressive pts |
SBRT dose (Gy) 40 (18–60) SBRT in five fractions (2–8) |
Median PFS was 7.8 (95% CI 4.6–10.9) months | Local failurewas 5% at 1 year and 7.3% at 2 years | Median OS was 25.1 (95% CI 11.2–39.1) months |
| Weikamp F, 2020 [34] | 46 pts Only MBC Both oligometastatic and oligoprogressive |
Median biologically effective dose (BED at α/β = 10) was 81.6 Gy (range: 45–112.5 Gy) | Median PFS at 2 years was 17% | At 2 years, local control (LC) was 89% | Median OS at 2 years was 62% |
| Nicosia L, 2022 [35] | 79 pts Only MBC Only oligoprogressive |
Only SBRT | NA | The 2-year FLP in the overall population was 86.7% | NA |
| Tan H, 2021 [36] | 129 pts Only MBC Both oligometastases, oligoprogression, and local control of dominant tumor (CDT) |
Extra-cranial SBRT to metastatic lesions | 1-year PFS for oligoprogression, was 19.6% | 1- and 2-year LC rates were 89% and 86.6% | 1- and 2-year OS rates were 83.5% and 70% |